Kalevi Kurkijärvi

Fibrogen Europe Oy develops and markets recombinant human collagens and gelatins for research purposes. It serves companies in the pharmaceutical, vaccine, medical device, diagnostic, industrial, food, cosmetic, and nutraceutical businesses. The company was founded on May 22, 1996 and is located at Helsinki, Finland.

Paratek Pharmaceuticals, Inc. operates as a pharmaceutical company that focuses on the discovery, development, and commercialization of medicines. The firm’s lead product candidate, omadacycline, is a new tetracycline-derived, broad-spectrum antibiotic being developed for use as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern for treating physicians. The company was founded by Stuart B. Levy and Walter A. Gilbert on July 3, 1996 and is headquartered in Boston, MA.

Paratek Pharmaceuticals, Inc. operates as a pharmaceutical company that focuses on the discovery, development, and commercialization of medicines. The firm’s lead product candidate, omadacycline, is a new tetracycline-derived, broad-spectrum antibiotic being developed for use as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern for treating physicians. The company was founded by Stuart B. Levy and Walter A. Gilbert on July 3, 1996 and is headquartered in Boston, MA.

Innomedica is an international business consulting company serving the biotechnology and pharmaceutical industries. It provides a range of professional business development and project management services to its clients in both the public and private sectors. Innomedica's service portfolio includes Business Development, Licensing & Partnering, Japan Markets and Project Management. It is active on a global basis, though it specializes in the North European and Japanese markets. Its people are its main asset. Its success is based on leveraging the experience of professionals from different disciplines to deliver value to its clients. Its team portrays backgrounds from experienced business people to skilled lawyers and biomedical scientists. Innomedica was founded in 1997, and is a privately held company. Its client base covers both private and public sectors, both large and small.

Paratek Pharmaceuticals, Inc. operates as a pharmaceutical company that focuses on the discovery, development, and commercialization of medicines. The firm’s lead product candidate, omadacycline, is a new tetracycline-derived, broad-spectrum antibiotic being developed for use as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern for treating physicians. The company was founded by Stuart B. Levy and Walter A. Gilbert on July 3, 1996 and is headquartered in Boston, MA.

Paratek Pharmaceuticals, Inc. operates as a pharmaceutical company that focuses on the discovery, development, and commercialization of medicines. The firm’s lead product candidate, omadacycline, is a new tetracycline-derived, broad-spectrum antibiotic being developed for use as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern for treating physicians. The company was founded by Stuart B. Levy and Walter A. Gilbert on July 3, 1996 and is headquartered in Boston, MA.

Fibrogen Europe Oy develops and markets recombinant human collagens and gelatins for research purposes. It serves companies in the pharmaceutical, vaccine, medical device, diagnostic, industrial, food, cosmetic, and nutraceutical businesses. The company was founded on May 22, 1996 and is located at Helsinki, Finland.

Hytest Oy manufactures biological products. It operates as producer of monoclonal antibodies and antigens for the diagnostic industry. The company was founded in 1994 and is headquartered in Turku, Finland.

Innomedica is an international business consulting company serving the biotechnology and pharmaceutical industries. It provides a range of professional business development and project management services to its clients in both the public and private sectors. Innomedica's service portfolio includes Business Development, Licensing & Partnering, Japan Markets and Project Management. It is active on a global basis, though it specializes in the North European and Japanese markets. Its people are its main asset. Its success is based on leveraging the experience of professionals from different disciplines to deliver value to its clients. Its team portrays backgrounds from experienced business people to skilled lawyers and biomedical scientists. Innomedica was founded in 1997, and is a privately held company. Its client base covers both private and public sectors, both large and small.

Paratek Pharmaceuticals, Inc. operates as a pharmaceutical company that focuses on the discovery, development, and commercialization of medicines. The firm’s lead product candidate, omadacycline, is a new tetracycline-derived, broad-spectrum antibiotic being developed for use as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern for treating physicians. The company was founded by Stuart B. Levy and Walter A. Gilbert on July 3, 1996 and is headquartered in Boston, MA.

BioFund Management Oy is a venture capital and private equity investment firm headquartered in Helsinki with an office in Turku and a subsidiary in Copenhagen. BioFund was founded in 1997 by Dr. Kalevi Kurkijärvi, Seppo Mäkinen and Dr. Timo Petäjä. BioFund's main investors are institutions in Finland such as insurance firms, pension funds, foundations, and the European Investment Fund. The firm manages venture capital funds.

Innomedica is an international business consulting company serving the biotechnology and pharmaceutical industries. It provides a range of professional business development and project management services to its clients in both the public and private sectors. Innomedica's service portfolio includes Business Development, Licensing & Partnering, Japan Markets and Project Management. It is active on a global basis, though it specializes in the North European and Japanese markets. Its people are its main asset. Its success is based on leveraging the experience of professionals from different disciplines to deliver value to its clients. Its team portrays backgrounds from experienced business people to skilled lawyers and biomedical scientists. Innomedica was founded in 1997, and is a privately held company. Its client base covers both private and public sectors, both large and small.

Paratek Pharmaceuticals, Inc. operates as a pharmaceutical company that focuses on the discovery, development, and commercialization of medicines. The firm’s lead product candidate, omadacycline, is a new tetracycline-derived, broad-spectrum antibiotic being developed for use as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern for treating physicians. The company was founded by Stuart B. Levy and Walter A. Gilbert on July 3, 1996 and is headquartered in Boston, MA.

Innomedica is an international business consulting company serving the biotechnology and pharmaceutical industries. It provides a range of professional business development and project management services to its clients in both the public and private sectors. Innomedica's service portfolio includes Business Development, Licensing & Partnering, Japan Markets and Project Management. It is active on a global basis, though it specializes in the North European and Japanese markets. Its people are its main asset. Its success is based on leveraging the experience of professionals from different disciplines to deliver value to its clients. Its team portrays backgrounds from experienced business people to skilled lawyers and biomedical scientists. Innomedica was founded in 1997, and is a privately held company. Its client base covers both private and public sectors, both large and small.

Innomedica is an international business consulting company serving the biotechnology and pharmaceutical industries. It provides a range of professional business development and project management services to its clients in both the public and private sectors. Innomedica's service portfolio includes Business Development, Licensing & Partnering, Japan Markets and Project Management. It is active on a global basis, though it specializes in the North European and Japanese markets. Its people are its main asset. Its success is based on leveraging the experience of professionals from different disciplines to deliver value to its clients. Its team portrays backgrounds from experienced business people to skilled lawyers and biomedical scientists. Innomedica was founded in 1997, and is a privately held company. Its client base covers both private and public sectors, both large and small.

Innomedica is an international business consulting company serving the biotechnology and pharmaceutical industries. It provides a range of professional business development and project management services to its clients in both the public and private sectors. Innomedica's service portfolio includes Business Development, Licensing & Partnering, Japan Markets and Project Management. It is active on a global basis, though it specializes in the North European and Japanese markets. Its people are its main asset. Its success is based on leveraging the experience of professionals from different disciplines to deliver value to its clients. Its team portrays backgrounds from experienced business people to skilled lawyers and biomedical scientists. Innomedica was founded in 1997, and is a privately held company. Its client base covers both private and public sectors, both large and small.

Hytest Oy manufactures biological products. It operates as producer of monoclonal antibodies and antigens for the diagnostic industry. The company was founded in 1994 and is headquartered in Turku, Finland.

Paratek Pharmaceuticals, Inc. operates as a pharmaceutical company that focuses on the discovery, development, and commercialization of medicines. The firm’s lead product candidate, omadacycline, is a new tetracycline-derived, broad-spectrum antibiotic being developed for use as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern for treating physicians. The company was founded by Stuart B. Levy and Walter A. Gilbert on July 3, 1996 and is headquartered in Boston, MA.

Paratek Pharmaceuticals, Inc. operates as a pharmaceutical company that focuses on the discovery, development, and commercialization of medicines. The firm’s lead product candidate, omadacycline, is a new tetracycline-derived, broad-spectrum antibiotic being developed for use as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern for treating physicians. The company was founded by Stuart B. Levy and Walter A. Gilbert on July 3, 1996 and is headquartered in Boston, MA.

Paratek Pharmaceuticals, Inc. operates as a pharmaceutical company that focuses on the discovery, development, and commercialization of medicines. The firm’s lead product candidate, omadacycline, is a new tetracycline-derived, broad-spectrum antibiotic being developed for use as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern for treating physicians. The company was founded by Stuart B. Levy and Walter A. Gilbert on July 3, 1996 and is headquartered in Boston, MA.